Clermont

Researchers are evaluating the safety and tolerability of epcoritamab combined with various anti-cancer drugs in adults with Non-Hodgkin lymphoma (NHL), a rare and aggressive cancer of certain white blood cells. This study involves participants with different types of NHL, including diffuse large B-cell lymphoma, follicular lymphoma, and mantle cell lymphoma. The research will assess adverse events and changes in disease activity over time to better understand the treatment's effects. Participants are assigned to different treatment groups based on their specific NHL type and prior treatments. They will receive subcutaneous injections of epcoritamab combined with oral or intravenous anti-neoplastic agents such as lenalidomide, ibrutinib, rituximab, cyclophosphamide, doxorubicin hydrochloride, prednisone, polatuzumab vedotin, and CC-99282. Treatment cycles vary between 21, 28, or 56 days depending on the group. The study includes both dose escalation and dose expansion phases, exploring different combinations of these drugs. During the study, participants will attend regular visits at hospitals or clinics for medical assessments, blood tests, and questionnaires to monitor side effects and treatment impact. Researchers will track dose-limiting toxicities for up to five years. The overall treatment burden may be higher than standard care due to frequent visits and evaluations. Approximately 496 adult participants will be enrolled across about 100 sites worldwide to provide comprehensive data on the safety and effects of these treatment combinations.

Liver transplantation is a complex surgery that carries a risk of bleeding and complications related to blood clotting. Researchers are studying the factors that influence bleeding and the need for blood transfusions during and after liver transplantation. This study aims to improve understanding by using new predictive methods such as Bayesian inference and machine learning, as current models mainly rely on preoperative data and do not fully consider the different phases of surgery. The study also seeks to describe how bleeding and anticoagulation are managed in liver transplant patients across metropolitan France. The study is observational and takes place across multiple centers. It follows liver transplant patients to monitor intraoperative bleeding and transfusion needs during the three phases of surgery: dissection, anhepatic, and neohepatic. Researchers will evaluate the number of packed red blood cell transfusions given during surgery and analyze risk factors for bleeding and thrombosis. The study does not involve experimental treatments but focuses on collecting data to better predict and manage bleeding risks. Participants will be monitored throughout the surgery and postoperatively to gather detailed information on bleeding events, transfusion amounts, and anticoagulation practices. The main outcome measured is the number of red blood cell units transfused during surgery. This prospective study will help identify predictive factors for bleeding and clotting complications, potentially guiding future care improvements. The study includes adult liver transplant patients and excludes those undergoing multiple organ transplants or without social security coverage.